Investor News

May 20, 2013
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:

Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat more

Riociguat showed good long-term safety profile (1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH) (1)

May 17, 2013
Not intended for U.S. and UK Media

Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan more

May 16, 2013
Strategic move to strengthen Consumer Care business:

Bayer to acquire Steigerwald Arzneimittelwerk GmbH more

News Overview

Highlights

April 26, 2013: Annual Stockholders' Meeting of Bayer AG 

The Annual Stockholders’ Meeting was held on Friday, April 26, 2012 in Cologne.

Voting Results

Video recording of the speech

Dividend

April 26, 2013: Publication of the Sustainable Development Report 2012 

Our Sustainable Development Report for 2012 documents in detail the company's performance in the field of sustainability. Its six chapters – Strategy & Focus Issues, Management & Corporate Governance, Innovation & Product Stewardship, Employees, Ecology and Social Commitment – illustrate how the Group combines commercial success with meeting social and ecological demands.

Online version

Download and print:   PDF / 3.11 MB collectBayer-Sustainable-Development-Report-2012.pdf Sustainable Development Report 2012pdf

News Release

Key Topics

Investor Services

Last updated: April 26, 2013  Copyright © Bayer AG
http://www.bayer.com